• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.HPV DNA 基因芯片分型检测与 Cobas 4800 HPV 检测和细胞学比较在 CIN2+中的检测。
Virol J. 2019 Jul 23;16(1):92. doi: 10.1186/s12985-019-1197-6.
2
The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.人乳头瘤病毒 16/18 型基因分型杂交捕获法在宫颈癌筛查初筛中检测人乳头瘤病毒 DNA 的性能:10669 例中国女性的横断面研究。
Clin Microbiol Infect. 2018 Dec;24(12):1322-1327. doi: 10.1016/j.cmi.2018.02.027. Epub 2018 Mar 5.
3
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.25 岁及以上女性宫颈癌筛查中致癌型人乳头瘤病毒(HPV)检测及 HPV16 或 HPV18 基因分型的性能:ATHENA 研究的一项亚组分析。
Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.
4
Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.SureX HPV 基因分型检测在宫颈癌筛查中检测高危型 HPV 的评估。
Virol J. 2020 Nov 9;17(1):171. doi: 10.1186/s12985-020-01417-8.
5
Clinical performance of the HPV DNA Array genotyping assay in detection of CIN2+ lesions with BS GP5+/6+ MPG Luminex tested cervical samples.HPV DNA 基因芯片分析在 BS GP5+/6+ MPG Luminex 检测的宫颈样本检测 CIN2+病变中的临床性能。
J Med Virol. 2020 Jan;92(1):113-118. doi: 10.1002/jmv.25583. Epub 2019 Sep 8.
6
Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.关于雅培实时高危型人乳头瘤病毒检测在宫颈癌筛查中的临床性能的三年纵向数据。
J Clin Virol. 2016 Mar;76 Suppl 1:S29-S39. doi: 10.1016/j.jcv.2015.11.021. Epub 2015 Nov 19.
7
Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.SurePath 介质中使用 VALGENT-4 试剂盒的 HPV-Risk assay 在宫颈样本中的临床性能。
J Clin Virol. 2019 Dec;121:104201. doi: 10.1016/j.jcv.2019.104201. Epub 2019 Oct 12.
8
Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening.罗氏 cobas HPV 检测在罗氏 cobas 5800 系统上用于宫颈癌筛查的临床验证。
Microbiol Spectr. 2024 Oct 3;12(10):e0149324. doi: 10.1128/spectrum.01493-24. Epub 2024 Sep 11.
9
Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.杂交捕获II检测法与人乳头瘤病毒DNA芯片检测法在检测高级别宫颈病变中的比较。
Int J Gynecol Cancer. 2009 Jul;19(5):924-8. doi: 10.1111/IGC.0b013e3181a832a2.
10
[Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].[BMRT-HPV用于宫颈癌筛查的有效性评估]
Zhonghua Fu Chan Ke Za Zhi. 2020 Oct 25;55(10):708-715. doi: 10.3760/cma.j.cn112141-20200325-00266.

引用本文的文献

1
Human papillomavirus positivity and cervical lesions in relation to HIV infection: a comparative assessment in the Cameroonian female population.人类乳头瘤病毒阳性及宫颈病变与艾滋病毒感染的关系:喀麦隆女性人群的比较评估
J Public Health Afr. 2023 Oct 1;14(9):2334. doi: 10.4081/jphia.2023.2334.
2
High-Risk Human Papillomavirus Detection via Cobas 4800 and REBA HPV-ID Assays.基于 Cobas 4800 系统和 REBA HPV-ID 检测试剂盒的高危型人乳头瘤病毒检测。
Viruses. 2022 Dec 3;14(12):2713. doi: 10.3390/v14122713.
3
Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.HPV 自我采样装置 Qvintip 和 HerSwab 在未参加宫颈癌筛查项目女性中的随访长期结果。
Radiol Oncol. 2021 Jan 6;55(2):187-195. doi: 10.2478/raon-2021-0001.
4
Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.SureX HPV 基因分型检测在宫颈癌筛查中检测高危型 HPV 的评估。
Virol J. 2020 Nov 9;17(1):171. doi: 10.1186/s12985-020-01417-8.
5
Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions.宫颈病变中鳞状细胞癌抗原(SCCA)、转移相关蛋白1(MTA1)、P16、Ki-67的表达与高危型人乳头瘤病毒(HPV)感染之间的关系。
Oncol Lett. 2020 Jul;20(1):884-892. doi: 10.3892/ol.2020.11634. Epub 2020 May 18.
6
Home-based HPV self-sampling assisted by a cloud-based electronic data system: Lessons learnt from a pilot community cervical cancer screening campaign in rural Ethiopia.基于云的电子数据系统辅助下的家庭 HPV 自我采样:来自埃塞俄比亚农村社区宫颈癌筛查试点活动的经验教训。
Papillomavirus Res. 2020 Jun;9:100198. doi: 10.1016/j.pvr.2020.100198. Epub 2020 May 8.

本文引用的文献

1
Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.人乳头瘤病毒持续感染妇女的管理:一项随机临床试验的长期随访。
Am J Obstet Gynecol. 2017 Mar;216(3):264.e1-264.e7. doi: 10.1016/j.ajog.2016.10.042. Epub 2016 Nov 5.
2
Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment.在高级别宫颈上皮内瘤变(CIN)女性患者治疗前后,对其宫颈、阴道和尿液样本进行Cobas 4800人乳头瘤病毒(HPV)检测。
J Clin Pathol. 2015 Jul;68(7):567-70. doi: 10.1136/jclinpath-2014-202851. Epub 2015 Apr 15.
3
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.基于高危型人乳头瘤病毒(HPV)检测以及HPV 16和HPV 18基因分型的宫颈癌初筛,与细胞学检查的比较。
PLoS One. 2015 Mar 20;10(3):e0119755. doi: 10.1371/journal.pone.0119755. eCollection 2015.
4
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.人乳头瘤病毒用于宫颈癌一线筛查的 ATHENA 研究:研究结束时的结果
Gynecol Oncol. 2015 Feb;136(2):189-97. doi: 10.1016/j.ygyno.2014.11.076. Epub 2015 Jan 8.
5
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.原发性高危型人乳头瘤病毒检测用于宫颈癌筛查:临时临床指南
J Low Genit Tract Dis. 2015 Apr;19(2):91-6. doi: 10.1097/LGT.0000000000000103.
6
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.人乳头瘤病毒检测结果不一致:初次宫颈癌筛查中检测方法选择面临的意外挑战。
PLoS One. 2014 Jan 20;9(1):e86835. doi: 10.1371/journal.pone.0086835. eCollection 2014.
7
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.HPV 阴性女性保护作用的长期持续时间:原发性 HPV 筛查随机对照试验的随访。
BMJ. 2014 Jan 16;348:g130. doi: 10.1136/bmj.g130.
8
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.HPV 检测在宫颈癌筛查中的效果:四项欧洲随机对照试验的随访研究。
Lancet. 2014 Feb 8;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3.
9
Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.评价一种用于致癌型人乳头瘤病毒(HPV)检测和同时进行 HPV16(人乳头瘤病毒 16 型)和 HPV18 基因型分型的实时 PCR 检测方法的原型。
J Clin Microbiol. 2009 Oct;47(10):3344-7. doi: 10.1128/JCM.00725-09. Epub 2009 Aug 12.
10
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.30岁及以上女性原发性宫颈癌筛查中人乳头瘤病毒DNA检测要求指南。
Int J Cancer. 2009 Feb 1;124(3):516-20. doi: 10.1002/ijc.24010.

HPV DNA 基因芯片分型检测与 Cobas 4800 HPV 检测和细胞学比较在 CIN2+中的检测。

CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.

机构信息

Gynaecology Clinic, Charité Universitätsmedizin, Corporate member of Freie Universität Berlin, Humboldt-Universität Berlin and Berlin Institute of Health, Hindenburgdamm 30, 12200, Berlin, Germany.

AID/GenID Diagnostika, Ebinger Strasse 4, 72479, Strassberg, Germany.

出版信息

Virol J. 2019 Jul 23;16(1):92. doi: 10.1186/s12985-019-1197-6.

DOI:10.1186/s12985-019-1197-6
PMID:31337408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6651913/
Abstract

BACKGROUND

HPV DNA Array is an E1-targeting PCR genotyping test, with capability of distinguishing 18 high-risk (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) and 11 low-risk HPV types (6, 11, 40, 42, 44, 54, 67, 69, 70, 85, 97). HPV DNA Array uses multiplex PCR for E1-gene sequence amplification. The amplicons are detected and genotyped by reverse hybridization to immobilized DNA probes spotted as triplets in single 96 well-plate wells and read by AID ELISPOT reader.

METHODS

Aim of the study was to evaluate the clinical performance of the assay against internationally accepted and FDA approved Cobas 4800 HPV test (Roche Diagnostics). Study population comprised of 500 cervical samples.

RESULTS

HPV DNA Array demonstrated a very high sensitivity of 100% for CIN2+ and 100% for CIN3+ detection, same as Cobas 4800. HPV DNA Array showed greater sensitivity for CIN2+ detection than cytology (100% vs. 13.6%). The agreement to Cobas 4800 for HPV detection, irrespective of type, was 81.4% with κ = 0.613. The agreement for HPV 16 was 92.8% (κ = 0.929), and for HPV 18 54.2% (κ = 0.681).

CONCLUSION

HPV DNA Array demonstrated good clinical performance for detection of high-grade lesions, and may be considered for usage in a screening setting.

摘要

背景

HPV DNA 芯片是一种针对 E1 靶向的 PCR 基因分型检测,能够区分 18 种高危型(16、18、26、31、33、35、39、45、51、52、53、56、58、59、66、68、73、82)和 11 种低危型 HPV(6、11、40、42、44、54、67、69、70、85、97)。HPV DNA 芯片采用多重 PCR 对 E1 基因序列进行扩增。扩增产物通过反向杂交固定在 DNA 探针上进行检测和基因分型,这些探针以三联体的形式点样于单个 96 孔板的孔中,并通过 AID ELISPOT 读取器进行读取。

方法

本研究旨在评估该检测方法与国际公认和 FDA 批准的 Cobas 4800 HPV 检测(罗氏诊断)相比的临床性能。研究人群包括 500 例宫颈样本。

结果

HPV DNA 芯片对 CIN2+和 CIN3+的检测灵敏度均为 100%,与 Cobas 4800 相同。HPV DNA 芯片对 CIN2+的检测灵敏度高于细胞学(100% vs. 13.6%)。HPV 检测与 Cobas 4800 的一致性,无论 HPV 类型如何,均为 81.4%,κ 值为 0.613。HPV 16 的一致性为 92.8%(κ 值为 0.929),HPV 18 的一致性为 54.2%(κ 值为 0.681)。

结论

HPV DNA 芯片在检测高级别病变方面具有良好的临床性能,可考虑用于筛查。